- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
SET-PP2A complex as a new therapeutic target in KMT2A (MLL) rearranged AML ; volume:42 ; number:50 ; day:27 ; month:10 ; year:2023 ; pages:3670-3683 ; date:12.2023
Oncogene ; 42, Heft 50 (27.10.2023), 3670-3683, 12.2023
- Urheber
-
Mambro, Antonella Di
Arroyo-Berdugo, Yoana
Fioretti, Tiziana
Randles, Michael
Cozzuto, Luca
Rajeeve, Vinothini
Cevenini, Armando
Austin, Michael J.
Esposito, Gabriella
Ponomarenko, Julia
Lucas, Claire M.
Cutillas, Pedro
Gribben, John G.
Williams, Owen
Calle, Yolanda
Patel, Bela
Esposito, Maria Teresa
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41388-023-02840-1
- URN
-
urn:nbn:de:101:1-2024022609503678282977
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:01 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Mambro, Antonella Di
- Arroyo-Berdugo, Yoana
- Fioretti, Tiziana
- Randles, Michael
- Cozzuto, Luca
- Rajeeve, Vinothini
- Cevenini, Armando
- Austin, Michael J.
- Esposito, Gabriella
- Ponomarenko, Julia
- Lucas, Claire M.
- Cutillas, Pedro
- Gribben, John G.
- Williams, Owen
- Calle, Yolanda
- Patel, Bela
- Esposito, Maria Teresa
- SpringerLink (Online service)
Ähnliche Objekte (12)
Molecular pathogenesis of disease progression in MLL-rearranged AML
Reversal of MYB-dependent suppression of MAFB expression overrides leukaemia phenotype in MLL-rearranged AML
RNA binding proteins in MLL-rearranged leukemia
Using genome editing to model MLL rearranged leukemias
NG2 antigen is a therapeutic target for MLL-rearranged B-cell acute lymphoblastic leukemia
Therapeutic strategies against hDOT1L as a potential drug target in MLL-rearranged leukemias
The epigenetic regulators EP300/CREBBP represent promising therapeutic targets in MLL-rearranged acute myeloid leukemia
The small inhibitor WM-1119 effectively targets KAT6A-rearranged AML, but not KMT2A-rearranged AML, despite shared KAT6 genetic dependency
Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia
FBXO22 promotes leukemogenesis by targeting BACH1 in MLL-rearranged acute myeloid leukemia
Targeting the histone H3 lysine 79 methyltransferase DOT1L in MLL-rearranged leukemias
Functional diversity of inhibitors tackling the differentiation blockage of MLL-rearranged leukemia
Molecular pathogenesis of disease progression in MLL-rearranged AML
Reversal of MYB-dependent suppression of MAFB expression overrides leukaemia phenotype in MLL-rearranged AML
RNA binding proteins in MLL-rearranged leukemia
Using genome editing to model MLL rearranged leukemias
NG2 antigen is a therapeutic target for MLL-rearranged B-cell acute lymphoblastic leukemia
Therapeutic strategies against hDOT1L as a potential drug target in MLL-rearranged leukemias
The epigenetic regulators EP300/CREBBP represent promising therapeutic targets in MLL-rearranged acute myeloid leukemia
The small inhibitor WM-1119 effectively targets KAT6A-rearranged AML, but not KMT2A-rearranged AML, despite shared KAT6 genetic dependency
Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia
FBXO22 promotes leukemogenesis by targeting BACH1 in MLL-rearranged acute myeloid leukemia
Targeting the histone H3 lysine 79 methyltransferase DOT1L in MLL-rearranged leukemias
Functional diversity of inhibitors tackling the differentiation blockage of MLL-rearranged leukemia
Molecular pathogenesis of disease progression in MLL-rearranged AML
Reversal of MYB-dependent suppression of MAFB expression overrides leukaemia phenotype in MLL-rearranged AML
RNA binding proteins in MLL-rearranged leukemia
Using genome editing to model MLL rearranged leukemias
NG2 antigen is a therapeutic target for MLL-rearranged B-cell acute lymphoblastic leukemia
Therapeutic strategies against hDOT1L as a potential drug target in MLL-rearranged leukemias
The epigenetic regulators EP300/CREBBP represent promising therapeutic targets in MLL-rearranged acute myeloid leukemia
The small inhibitor WM-1119 effectively targets KAT6A-rearranged AML, but not KMT2A-rearranged AML, despite shared KAT6 genetic dependency
Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia
FBXO22 promotes leukemogenesis by targeting BACH1 in MLL-rearranged acute myeloid leukemia
Targeting the histone H3 lysine 79 methyltransferase DOT1L in MLL-rearranged leukemias